Narrow Vote Calls for Keeping Drug Safety Trials, but Many See Changes

A decade after they began, large cardiovascular outcomes trials (CVOTs) will likely remain part of the process for companies that develop type 2 diabetes (T2D) drugs. But following last week’s narrow vote of an FDA panel, it seems likely the trials may b https://www.ajmc.com/focus-of-the-week/narrow-vote-calls-for-keeping-drug-safety-trials-but-many-see-changes